US Patent 6,660,300 Landscape: Scope, Claim Breadth, and Expiration/Orange Book Relevance for Biphasic Extended-Release Metformin
US Patent 6,660,300 is directed to once-daily metformin-containing diabetes treatment using a biphasic heterogeneous controlled-release formulation. The core structural limitation is a two-phase solid system: an inner solid particulate phase containing metformin (high water solubility salt forms) plus extended-release material, embedded and dispersed in an outer solid continuous phase containing extended-release material, with the total extended-release material content constrained to about 25% to about 75% by weight (and narrower subranges in dependent claims). The independent-method claims also lock in pharmacokinetic performance (lowered Cmax, increased Tmax, no meaningful AUC/urinary recovery change) in at least one dependent claim.
This claim architecture creates (1) strong product-formulation encroachment through the biphasic ER-material/content constraints and ER-material “partitioning” between inner and outer phases, but (2) a potentially narrower enforcement posture because many claim limits are material-composition and ratio specific, including defined ER-polymer classes and viscosity grades, and in some places a defined GI release path (“upper gastrointestinal tract”) and PK thresholds.
What does US Patent 6,660,300 claim for metformin controlled release?
What is the invention, in plain claim mechanics?
The claims are method claims, but they are method-of-treatment claims whose operative step is the administration of a specific formulation. The formulation is defined by:
-
Biphasic solid morphology
- Inner solid particulate phase (discrete particles/granules)
- Outer solid continuous phase (a substantially continuous matrix)
- Particles dispersed and embedded in the outer matrix
-
Metformin in the inner phase
- Metformin or pharmaceutically acceptable salts, including:
- metformin hydrochloride
- metformin fumarate (2:1)
- metformin succinate (2:1)
- other salt forms are contemplated by claim genus language
-
Extended-release materials in both phases
- Both phases contain “extended release material”
- A key limitation is that the total ER-material content across both phases is about 25% to about 75% by weight of the formulation
- Dependent claims narrow the content range (example: 30%–65%, 35%–60%)
-
ER-material partitioning
- Some dependent claims require inner and outer ER materials are different (composition differentiation is a distinct limitation)
-
Optional performance and regimen constraints
- “once daily” administration
- dosing regimens that permit ≥ 1 g once daily and optionally 1–3 g once daily
- GI release design: “release into the upper gastrointestinal tract”
- PK endpoints: Cmax down ≥15%, Tmax up ≥30%, AUC and UR “insignificant effect”
Where does the formulation boundary sit? (Key independent claim logic)
Independent claims you provided function as:
- Claim 1 (diabetes method): biphasic solid formulation with:
- inner particulate: metformin + ER-material
- outer continuous: ER-material
- total ER-material content 25%–75%
- Claim 27 (diabetes method): same biphasic formulation concept but explicitly requires ER-material in inner is different from ER-material in outer, and retains total ER-material content 25%–75%
- Claims 48–60 (insulin resistance methods): parallel the diabetes claims, replacing “treating diabetes” with “lowering insulin resistance,” with essentially the same formulation constraints and the same PK constraints appearing in dependent claims.
Impact: This yields two enforcement “lanes”:
- A lane that only requires the biphasic ER-material/content architecture (Claim 1).
- A lane that additionally requires inner/outer ER materials differ (Claim 27 and its insulin-resistance counterpart).
How broad are the scope and claim coverage in US 6,660,300?
Breadth drivers (what defendants must avoid)
-
Metformin genus coverage
- Covers metformin itself and multiple salts.
- Salt selection does not appear to be the primary escape vector because claims include multiple specific salt exemplars.
-
ER-material “category” breadth
- Claims often speak in polymer/material genera:
- hydrophilic polymers
- hydrophobic polymers
- “one or more other hydrophobic materials”
- This creates breadth at the top level, but breadth narrows in dependent claims that cite specific ionic vs non-ionic polymers and named excipient polymers.
-
Morphology breadth
- Requires inner particulate and outer continuous matrix with embedded particles.
- Many controlled-release granule-in-matrix designs will map onto this basic biphasic morphology.
-
Total ER-material content window
- The top-line window 25%–75% by weight is a practical quantitative guardrail.
- Many extended-release matrices/granule systems will fall inside that window, depending on how “extended release material” is defined by the patent and how formulations are categorized.
Breadth limiters (what narrows infringement)
-
Total ER-material content is a hard numeric limit
- If a competitor designs a lower ER-material fraction (or argues ER-material is not “extended release material” under the patent’s definition), the formulation can be outside the 25%–75% boundary.
-
Inner phase ER-material vs outer phase ER-material “different” limitation
- Claim 27’s extra limitation can be avoided by using the same ER material(s) in both phases or by selecting an alternative partitioning approach that negates “different” under claim construction.
-
Named polymer/viscosity grades in dependent claims
- Dependent claims recite:
- ionic polymers: sodium alginate, carbomer, calcium carboxymethylcellulose, sodium carboxymethylcellulose
- non-ionic polymers: HPMC 2208 (4000–100,000 cps) and/or HPMC 2910 (3–150 cps)
- A product that uses different polymer exemplars or differs outside those viscosity grades may avoid these dependent claims (though it can still infringe the broader independent claims).
-
Particle size numeric limit appears as a dependent claim
- “mean particle size 30 μm to 0.8 mm” is a constraint in claim 19.
- Morphology claims can still be infringed without meeting particle-size limitations if those limits are not needed for an asserted claim.
-
GI release and PK requirements are in dependent claims
- The “upper gastrointestinal tract” feature is in claim 2.
- PK endpoints appear in claim 8 (and repeated in claim 12 and claim 47).
- Those dependent claims provide narrower paths that require matching measured PK outcomes against “marketed rapid-release metformin formulations.”
Which dependent claims materially increase or decrease enforceability?
Enforceability enhancers (tighter, more testable limits)
- Claim 7/3: total ER-material subranges
- 30%–65% and 35%–60% by weight.
- Claim 7: inner phase ER-material fraction 5%–95%
- Outer continuous ER-material fraction 40%–100%.
- Claim 11/33: defined morphology
- Inner: discrete granules
- Outer: continuous matrix embedding.
- Claim 16–20 (ionic vs non-ionic partitioning with specific polymers/viscosity grades)
- Claim 17–19 and claim 18 are materially specific.
- Claim 8/12/47: PK performance
- Cmax down ≥15%
- Tmax up ≥30%
- AUC and urinary recovery “insignificant effect”
These tighten the infringement proof burden in litigation but can strengthen validity arguments versus prior art if the PK profile is used as a differentiator.
Enforceability reducers (easier workarounds)
- If an accused product:
- stays within the overall concept but uses ER-material outside “extended release material” definition (litigation claim construction issue),
- uses total ER-material outside 25%–75%,
- uses identical ER-material in inner and outer (to dodge Claim 27),
- avoids polymer exemplars/viscosity grades in the dependent claims,
then it can reduce exposure to dependent claims and potentially avoid some independent claims depending on how strictly “ER-material” is construed.
What patents and claim sets are likely related to US 6,660,300?
You provided only the claim text. No bibliographic data (filing date, assignee, patent family, continuations) is present, so a complete and accurate “landscape” cannot be generated from that alone.
What can be stated from the claim content alone is the technical cluster that the patent sits in:
Technical claim cluster likely shared by contemporaneous patents
- Metformin once-daily extended release
- Biphasic heterogeneous controlled release granule-in-matrix formulations
- Polymer-based ER matrices:
- HPMC viscosity-grade specific forms
- ionic polymers like alginates and carbomers
- hydrophilic/hydrophobic blends
- PK optimization (Cmax reduction with Tmax delay, preserving AUC)
This places the patent in the “formulation engineering” lane rather than novel API synthesis. In practice, related patents typically include:
- further dependent improvements on polymer selection, ratios, and particle size,
- process claims (granulation/matrix manufacturing),
- and additional formulation geometries, including coating and layering variants.
However, without the patent’s bibliographic identifiers, you cannot map the family or definitively enumerate US continuations/divisionals or counterpart filings.
Per your constraint set, this analysis provides no enumerated list of other patent numbers beyond US 6,660,300 itself.
When does US 6,660,300 lose exclusivity and what are the expiration drivers?
A complete exclusivity/timeline analysis requires the patent’s:
- grant date,
- earliest effective filing date,
- maintenance status,
- and whether any terminal disclaimers exist.
Those are not present in the prompt. Under your rules, no partial or guessed expiration timetable can be produced.
Is US 6,660,300 vulnerable to generic or Paragraph IV design-arounds?
Where generics can design around
Given the claim limitations, the practical design-around levers are:
-
Move ER-material total outside 25%–75%
- Reformulate to reduce total ER-material content if feasible.
-
Control ER-material partitioning
- For exposures under Claim 27: use the same ER-material(s) in inner and outer phases or eliminate the “inner different from outer” condition.
-
Change the inner/outer material identity and polymer classes
- Avoid the specific ionic/non-ionic combinations and viscosity grade specifics in dependent claims.
-
Adjust morphology and particle-size distributions
- Dependent claims such as mean particle size (30 μm to 0.8 mm) could be avoided by controlling particle-size distributions and granule properties, though the key independent claims do not require that size window.
Litigation posture
The most litigated formulation patents often hinge on claim construction for:
- what counts as “extended release material,”
- how to interpret “inner particulate” and “outer continuous” for heterogeneous matrices,
- whether ER materials are “different” when compositions overlap.
But those are claim-construction matters and require records from prosecution or litigation to assess.
What is the scope of “upper gastrointestinal tract” and PK claims in enforcement?
Upper GI release limitation
Claim 2 requires the formulation be designed to release metformin through the outer phase into the upper gastrointestinal tract.
In an infringement fight, this tends to require:
- dissolution/biorelevant release testing evidence, or
- product-specific GI transit and release modeling.
Pharmacokinetic limitation
Claim 8 (and duplicated in claim 12 and claim 47) requires:
- Cmax reduction ≥15% vs marketed rapid-release,
- Tmax increase ≥30%,
- AUC and urinary recovery “insignificant effect.”
This is a high bar because:
- it depends on comparative control products,
- it depends on study design and bioequivalence variability,
- and it typically turns on clinical study readouts.
Business impact
PK-dependent dependent claims can be harder for challengers to match intentionally, but they also can:
- strengthen patent differentiation against prior art formulations,
- create leverage in settlement when the defendant cannot easily demonstrate non-matching PK.
How does US 6,660,300 compare with typical metformin ER architectures (what competitors should map)?
Based on the claim structure, the nearest competitor architectures to “potentially in-range” are:
-
Granules of metformin + ER polymers placed into an ER matrix
- Fits inner particulate metformin + ER; outer matrix ER.
-
Biphasic heterogeneous tablets where a core granular phase is embedded in a sustained-release binder/continuous phase
- Fits the “embedded and dispersed” structure.
Designs that are more distant include:
- single-phase monolithic ER matrices where metformin and ER polymer are uniformly distributed (no inner/outer partition),
- coated drug-layer systems where extended-release is purely via coating layers rather than an inner particulate ER-containing phase embedded in an outer ER continuous matrix,
- liquid/suspension ER systems (not within these “solid particulate/continuous phase” definitions).
Key Takeaways
- US 6,660,300 is a formulation-centric, biphasic ER metformin claim set using an inner particulate phase embedded in an outer continuous matrix.
- Core quantitative limiter: total extended-release material content across both phases is 25%–75% by weight (with dependent narrower ranges).
- Two independent enforcement lanes: one without a “different inner vs outer ER material” requirement (Claim 1), and another that explicitly requires ER-material differences (Claim 27).
- Risk concentration is highest for products that preserve:
- biphasic morphology,
- metformin in the inner particulate,
- ER polymer presence in both phases,
- and total ER-material fraction within the claimed window.
- Design-arounds are most plausible by moving formulation composition outside the ER-material window and/or neutralizing the “inner ER differs from outer ER” requirement.
- PK and upper-GI release features are dependent, increasing evidentiary burden for infringement and strengthening differentiation rather than being universally required.
FAQs
-
Can a metformin ER tablet avoid US 6,660,300 by using the same ER polymer in both inner and outer phases?
Claim 27 requires ER-material in the inner particulate phase to be different from the ER-material in the outer continuous phase; using identical ER material may be relevant to that narrower lane.
-
How critical is the 25%–75% by weight extended-release material limitation?
It is central to the independent claim formula constraints and provides a primary quantitative design-around target.
-
Do the PK limitations (Cmax/Tmax/AUC) determine infringement?
They appear in dependent claims (e.g., claim 8/12/47 in your excerpt). Infringement depends on which claim is asserted.
-
Does the claim require a specific metformin salt form?
No single salt is required in the broadest independent formulation-language; metformin and multiple salts are included, with specific salts called out in dependent claims.
-
Are “upper gastrointestinal tract” release characteristics mandatory?
They are tied to specific dependent claims (e.g., claim 2) and thus depend on asserted claim scope.
References
No external patent, prosecution-history, or regulatory record sources were provided or cited in the prompt; therefore, no APA reference list can be generated without introducing uncited facts.
